INmune Bio (INMB) Q2 Loss Widens 110%

Source Motley_fool

Key Points

  • EPS (GAAP) loss widened significantly to $(1.05).

  • XPro failed to meet primary endpoints in its Phase 2 Alzheimer’s trial, but showed some positive signals in a biomarker-enriched subgroup.

  • Cash and cash equivalents increased to $33.4 million, primarily due to a $19 million equity offering.

  • These 10 stocks could mint the next wave of millionaires ›

INmune Bio (NASDAQ:INMB), a clinical-stage biotechnology company focused on developing immunotherapies for neurodegenerative and inflammatory diseases, released its earnings for the second quarter on August 7, 2025. The primary news was a major net loss, stemming from a $16.5 million impairment charge, and clinical data from its lead XPro program in Alzheimer’s failing primary endpoints in the main patient group. The loss widened from $(0.50) (GAAP) in the prior year. There was no revenue, in line with expectations for a pre-commercial biotech. Overall, the quarter brought major clinical and financial setbacks, with ongoing questions around regulatory timelines and financial sustainability. Cash reserves increased thanks to a new equity raise, giving some operational cushion but keeping capital needs in sharp focus for potential investors.

MetricQ2 2025Q2 2025 EstimateQ2 2024Y/Y Change
EPS (GAAP)$(1.05)$(0.38)$(0.50)(-110.0%)
Revenue (GAAP)$0.0$0.0$0.0
Research and Development Expenses$5.9 million$7.1 million(16.9%)
General and Administrative Expenses$2.3 million$2.8 million(17.9%)
Cash and Cash Equivalents (end of period)$33.4 million

Source: Analyst estimates for the quarter provided by FactSet.

Business Overview and Strategic Drivers

INmune Bio (NASDAQ:INMB) is developing therapies that leverage the innate immune system—a branch of immunity that forms the body's first line of defense—to address diseases like Alzheimer's, various cancers, and rare skin disorders. Its approach targets immune functions not exploited by most rivals, focusing on drugs that neutralize specific inflammation drivers or enhance the activity of “natural killer” (NK) cells in attacking tumors.

The company’s commercial success hinges on four main factors: successful advancement of its clinical pipeline, execution of regulatory approval paths (including orphan drug and accelerated pathways), and robust intellectual property protection. Pipeline progress and regulatory discussions will be critical, particularly as its programs approach late-stage trials in highly competitive markets for Alzheimer’s, oncology, and rare dermatological disorders.

Quarterly Highlights: Financials, Pipeline, and Key Developments

The net loss (GAAP) ballooned to $24.5 million, compared to approximately $9.7 million during the quarter ended June 30, 2024, mainly due to a one-time, $16.5 million impairment charge for acquired research assets. This reflects a downward reassessment of pipeline value, after lackluster clinical data from its lead program.

Research and development expenses (GAAP) fell to $5.9 million, compared to approximately $7.1 million during the quarter ended June 30, 2024, and General and administrative spending (GAAP) decreased to $2.3 million, compared to approximately $2.8 million during the quarter ended June 30, 2024. The company continues to report no meaningful revenue, in line with its ongoing clinical-stage status. Cash and cash equivalents reached $33.4 million by June 30, 2025, up from $20.922 million at December 31, 2024. This increase was mainly driven by a $19 million equity raise. The company’s pace of cash burn remains high, with net cash used in operations (GAAP) totaled $14.2 million for 6M 2025.

On the clinical front, the most notable event was the release of top-line results from the MINDFuL Phase 2 trial for XPro, designed to target neuroinflammation in early Alzheimer’s disease. The study failed to meet its main (primary) cognitive endpoints in the broader, intended trial population of 200 patients. There were “positive trends” in a pre-specified biomarker-enriched subgroup—those with two or more inflammatory markers—covering about half the trial participants. In this group, XPro demonstrated an effect size approaching 0.2 on cognitive endpoints in patients with MCI and early Alzheimer’s in the MINDFuL Phase 2 trial, but was underpowered and did not reach statistical significance. The ambiguity clouded the regulatory and commercial prospects for XPro in Alzheimer’s.

The company continued to push ahead in other parts of the pipeline. The CORDStrom program, which uses mesenchymal stromal cell (MSC) therapy aimed first at treating the rare disease recessive dystrophic epidermolysis bullosa (RDEB), made progress in manufacturing and intellectual property protection. The company secured a favorable patent opinion from the U.S. Patent Office and expanded commercial manufacturing capabilities through a partnership with Cell and Gene Therapy Catapult. Further, it advanced work toward submitting both U.S. and U.K. regulatory filings in 2026, and key trial data are expected later in the year. The company says BLA and MAA filings for CORDStrom in RDEB remain on track for mid-2026, contingent on pending clinical results and effective manufacturing scale-up.

INKmune, the company’s solid-tumor immunotherapy platform aimed at treating metastatic castration-resistant prostate cancer, also advanced. Phase II enrollment for this cancer therapy opened in early 2025, drawing in the first group of patients, with biomarker analysis showing successful natural killer cell activation. Manufacturing was completed for all necessary doses through the current stage. Early clinical findings indicate some disease control or reduction at the lesion level, and imaging updates are expected later in the year. The company is positioning INKmune for future randomized trials, using phase II data to shape the overall program design.

Leadership transition marked another key change. Dr. RJ Tesi retired as CEO, with David Moss, the former CFO, stepping in. An interim CFO and a new board chair were also appointed, reflecting a strategic shift toward more capital markets and operational expertise during a volatile period for the company.

Looking Ahead: Guidance and Watch List

No quantitative or financial guidance was provided for upcoming quarters or for the remainder of fiscal 2025. Company management highlighted anticipated milestones: an end-of-phase-2 FDA meeting for XPro in Alzheimer’s, the publication of full trial data, regulatory engagement on CORDStrom, a read-out for additional indications, and progress toward pivotal trials for INKmune in cancer indications.

The company does not currently pay a dividend.

Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,046%* — a market-crushing outperformance compared to 181% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of August 4, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin Moving With Stocks, But Ethereum’s Correlation Is FadingBitcoin has been showing notable correlation to the stock equities recently, but data shows Ethereum is charting a more independent path. Bitcoin & Ethereum Showing Different Degrees Of
Author  NewsBTC
7 Month 10 Day Thu
Bitcoin has been showing notable correlation to the stock equities recently, but data shows Ethereum is charting a more independent path. Bitcoin & Ethereum Showing Different Degrees Of
placeholder
Ripple’s $21 Trillion Dream: What Capturing 20% Of SWIFT Volume Means For XRPRipple Labs, a crypto payments company, continues to set its ambitions and those of XRP higher than ever as it edges closer to disrupting the global financial messaging giant SWIFT. After Ripple CEO
Author  NewsBTC
7 Month 14 Day Mon
Ripple Labs, a crypto payments company, continues to set its ambitions and those of XRP higher than ever as it edges closer to disrupting the global financial messaging giant SWIFT. After Ripple CEO
placeholder
Philippines' GDP Growth Rises to 5.5% in Second Quarter of 2025The Philippine economy expanded at a marginally faster pace in the second quarter of 2025, with GDP growing 5.5% year-on-year.
Author  Mitrade
8 Month 07 Day Thu
The Philippine economy expanded at a marginally faster pace in the second quarter of 2025, with GDP growing 5.5% year-on-year.
placeholder
Asia Stocks Cautious Before China Tariff Deadline; Australia Sets Record HighMost Asian stock markets were little changed on Monday as investors looked ahead to the looming expiration of the U.S.-China tariff truce, while Australian equities climbed to new highs on rate-cut expectations.
Author  FXStreet
3 hours ago
Most Asian stock markets were little changed on Monday as investors looked ahead to the looming expiration of the U.S.-China tariff truce, while Australian equities climbed to new highs on rate-cut expectations.
placeholder
Oil Prices Extend Losses as Traders Eye US-Russia Summit, Inflation DataOil prices declined in Asian trading on Monday, adding to sharp losses from last week as expectations of progress in U.S.-Russia talks dampened geopolitical risk premiums, while weak inflation data from China weighed on demand sentiment.
Author  FXStreet
3 hours ago
Oil prices declined in Asian trading on Monday, adding to sharp losses from last week as expectations of progress in U.S.-Russia talks dampened geopolitical risk premiums, while weak inflation data from China weighed on demand sentiment.
goTop
quote